Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2026BMC GastroenterologyOpen Access

Clinical characteristics of metabolic dysfunction-associated steatotic liver disease and its association with significant liver fibrosis in hospitalized patients with chronic hepatitis B: a single-center retrospective cross-sectional study

View Full Paper
Ask AI
Bookmark
Share

Authors

CWChun-Xia WangJKJun KangJZJiawei Zhang

Discussion

Loading...

Member takes

Overview

Cross-sectional study reveals no independent link between steatotic liver disease and significant fibrosis in chronic hepatitis B, indicating viral and demographic factors dominate risk.

Key Points

  • To characterize hospitalized patients with chronic hepatitis B and concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate whether MASLD independently associates with significant liver fibrosis.
  • Retrospectively evaluated 776 hospitalized patients with chronic hepatitis B at the Public Health Clinical Center of Chengdu between December 2020 and December 2024.
  • Categorized patients into hepatitis B alone versus hepatitis B with MASLD based on diagnostic criteria, measuring liver stiffness via FibroScan.
  • Performed multivariable logistic regression and sensitivity analyses restricting alanine aminotransferase and aspartate aminotransferase levels to ≤5 times the upper limit of normal.
  • Concomitant MASLD was identified in 203 of 776 patients (26.2%), who were younger, had shorter hospital stays, higher albumin and platelets, but lower rates of antiviral treatment.
  • MASLD was not independently associated with significant liver fibrosis in the primary multivariable model (OR = 1.473, 95% CI: 0.970–2.236; P = 0.069) or sensitivity analysis (OR = 1.374, 95% CI: 0.860–2.195; P = 0.183).
  • Older age, male sex, and elevated aspartate aminotransferase levels consistently predicted significant liver fibrosis, with no significant interaction between MASLD and antiviral therapy (P for interaction = 0.232).

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6aabb7c95f706d05830e71achttps://doi.org/10.1186/s12876-026-05290-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Metabolic dysfunction-associated steatotic liver disease in chronic hepatitis B patients: risks of severe liver disease and cardiovascular disease2026
  2. 2Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study2024 · 5 citations
  3. 3Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study2024 · 17 citations
  4. 4Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient‐Reported Outcomes2026 · 1 citations
  5. 5Diagnosing and defining MASLD in people living with chronic hepatitis B2026 · 2 citations